ArticleOphthalmology and therapy2026
Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a summary of the original research article "Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials." Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are eye diseases that can be treated with anti-vascular endothelial growth factor (anti-VEGF) therapies. As these therapies are given by injections into the eye, reducing the number of injections could reduce the treatment burden on patients and healthcare providers. Aflibercept 8 mg and faricimab treat-and-extend (T&E) may enable longer dosing intervals compared with other available anti-VEGF therapies for patients with DME and nAMD; however, they have not been compared against each other directly in clinical trials. This study used a statistical method called a network meta-analysis (NMA) to compare aflibercept 8 mg and faricimab T&E by synthesizing data from clinical trials, enabling an indirect comparison in the absence of head-to-head studies. Outcomes included the mean number of injections, changes in vision [best-corrected visual acuity (BCVA)] and changes in macula thickness [central subfield thickness (CST)]. CST should reduce if the treatment is working. On the basis of indirect comparison of available clinical trial data, this exploratory study found that there were significantly fewer injections with aflibercept 8 mg treatment compared with faricimab T&E over 2 years, for both patients with DME and nAMD, and there were no significant differences between the two medications for BCVA or CST changes. NMAs are based on indirect comparisons and therefore have limitations, and clinical trials or real-world studies would be required to confirm these conclusions. Please refer to the original article for further details on the methods and limitations of this analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.